StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)

StockNews.com initiated coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDAGet Free Report) in a research report issued on Friday. The firm set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald upped their target price on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st.

Get Our Latest Analysis on Vanda Pharmaceuticals

Vanda Pharmaceuticals Trading Down 1.2 %

Shares of VNDA stock opened at $5.02 on Friday. The company has a market capitalization of $292.15 million, a PE ratio of -62.75 and a beta of 0.77. The firm has a fifty day simple moving average of $5.52 and a 200-day simple moving average of $5.08. Vanda Pharmaceuticals has a twelve month low of $3.30 and a twelve month high of $6.75.

Vanda Pharmaceuticals (NASDAQ:VNDAGet Free Report) last announced its earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter. The firm had revenue of $50.47 million during the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. Equities research analysts predict that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. SageView Advisory Group LLC bought a new position in Vanda Pharmaceuticals during the 1st quarter valued at $34,000. Meeder Asset Management Inc. bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at $39,000. China Universal Asset Management Co. Ltd. boosted its stake in Vanda Pharmaceuticals by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 4,387 shares during the last quarter. SG Americas Securities LLC bought a new position in Vanda Pharmaceuticals during the 2nd quarter valued at $61,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Vanda Pharmaceuticals by 18.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 2,425 shares during the last quarter. 88.14% of the stock is currently owned by institutional investors.

About Vanda Pharmaceuticals

(Get Free Report)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Recommended Stories

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.